Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TATUM-T vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche, are seeking contraception, and have failed topical therapy
Prevention of pregnancy
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 m L/min) requiring dose adjustment
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethynodiol diacetate is rapidly deacetylated to ethynodiol and then extensively metabolized via reduction, hydroxylation, and conjugation; primary enzyme is CYP3A4. Ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes phase II conjugation (glucuronidation and sulfation).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
92-95% bound to albumin and alpha-1-acid glycoprotein
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.3-0.5 L/kg (indicating moderate tissue distribution; primarily in extracellular fluid)
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 90% (high first-pass metabolism negligible); Sublingual: 95%; Intravenous: 100%
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use is not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh class C (severe hepatic impairment) and in women with active liver disease. For Child-Pugh A or B, use is not recommended due to impaired hormone metabolism. If used, monitor liver function closely.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. For post-menarche adolescents, use the same standard adult dosing regimen. Safety and efficacy established in females aged 16-35 years.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use after menopause. No geriatric-specific dose adjustment is available.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially in women over 35 years of age). Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders: Venous thromboembolism, arterial thromboembolism (e.g., stroke, myocardial infarction); discontinue if symptoms occur.,Hepatic disease: Discontinue if jaundice develops; use with caution in patients with impaired liver function.,Risk of liver tumors (benign and malignant); discontinue if right upper quadrant pain or signs of intra-abdominal bleeding.,Elevated blood pressure: Monitor and discontinue if hypertension occurs.,Carbohydrate metabolism: May decrease glucose tolerance; monitor diabetic patients.,Hyperkalemia: Risk in patients with renal impairment or concomitant potassium-sparing diuretics due to drospirenone component; TATUM-T does not contain drospirenone, so minimal risk.,Gallbladder disease: May worsen existing disease.,Hereditary angioedema: May exacerbate.,Chloasma: May occur, avoid sun exposure.,Retinal thrombosis: Discontinue if unexplained partial or complete vision loss.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes per day) in women over 35 years of age
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions. Avoid excessive copper supplements as the IUD releases copper locally; systemic absorption is minimal but caution in Wilson's disease.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformations and embryotoxicity. In human pregnancy, therapeutic use of copper is generally not associated with major teratogenic risk when used within recommended doses. However, data are limited. For the first trimester, there is a theoretical risk of copper toxicity affecting organogenesis; for second and third trimesters, risks include potential for copper accumulation and fetal hepatic toxicity. Zinc is essential but high doses may interfere with copper absorption. Overall, use only if clearly needed.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Copper is excreted into breast milk in small amounts and is a normal component of human milk. Zinc is also excreted. The M/P ratio for copper is approximately 0.1-0.3 and for zinc is about 0.5-1.0. At therapeutic doses, TATUM-T is unlikely to cause adverse effects in a breastfed infant. However, caution is advised due to potential for copper or zinc accumulation if maternal doses are high. Consider monitoring infant copper/zinc levels if prolonged use.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No established dosage adjustments are recommended for TATUM-T during pregnancy. However, pregnancy may alter copper metabolism with increased ceruloplasmin, potentially leading to lower free copper levels. Monitor serum copper levels to ensure therapeutic efficacy and avoid deficiency. If copper levels drop, consider increasing dose under medical supervision. Zinc dosing may remain unchanged.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
TATUM-T is a copper-containing intrauterine device (IUD) for long-term contraception (up to 10 years). It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. Mechanism involves copper-induced sperm toxicity and inhibition of implantation. May be used in nulliparous women. Counsel patients about expected bleeding pattern changes: increased menstrual flow and spotting initially. Monitor for IUD expulsion or perforation, especially postpartum. Do not use in Wilson's disease or copper allergy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
TATUM-T provides effective contraception for up to 10 years but does not protect against STDs; use condoms for protection.,You may experience heavier periods and spotting, especially in the first 3-6 months after insertion.,Check for the IUD strings after each menstrual period to ensure it is in place.,If you miss a period or have symptoms of pregnancy, contact your healthcare provider immediately.,Insertion may cause cramps and discomfort that typically resolve within a few hours to days.,Seek medical attention if you have severe pelvic pain, foul-smelling discharge, or fever, which could indicate infection.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TATUM-T vs ALYACEN 7/7/7, answered by our medical review team.
TATUM-T is a Oral Contraceptive that works by TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TATUM-T and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TATUM-T is: One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TATUM-T and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TATUM-T is classified as Category C. TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformatio. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.